Previous Close | 25.70 |
Open | 13.90 |
Bid | 57.00 |
Ask | 66.40 |
Strike | 395.00 |
Expire Date | 2024-05-24 |
Day's Range | 13.90 - 25.70 |
Contract Range | N/A |
Volume | |
Open Interest | 4 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.